Cingulate Inc.
No enriched coverage for $CING in the last 7 days.
No SEC Form 4 filings for $CING in the last 30 days.
See all $CING insider activity →Cingulate Inc. (CING) shares rose more than 4% in overnight trading after the USPTO allowed a patent application for a “Trimodal, Precision-Timed Pulsatile Release Tablet” tied to its ADHD drug platform. CING said the allowed status follows a filing in Nov 2023 and comes ahead of an FDA decision on CTx-1301, with a May 31 PDUFA target date.
Cingulate Inc. (CING) filed its Q2 2026 10-Q. It reported $0 product revenue and a net loss of $5.87M for the three months ended June 30, 2026, versus a $4.98M net loss in the prior-year quarter. The company said it received an FDA complete response letter for CTx-1301 requesting additional CMC data and outlined CMC and launch preparation plans.
Cingulate Inc. (CING) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness Cash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advan
Recent CING coverage spans corporate actions, regulation and market movers.
USPTO allowance adds IP validation for CTx-1301 delivery technology ahead of the FDA PDUFA decision window.
FDA CMC-focused CRL increases regulatory timeline risk for CTx-1301, while cash runway and manufacturing/CMC work aim to mitigate delays.
The filing is a near-term catalyst for CTx-1301 regulatory timing and runway, with additional commercialization contracts that can de-risk launch execution if approval follows.
Board action removes a C-suite legal function and signals a potential shift in governance, compliance, or legal resourcing.
Board restructuring and an equity plan share increase can affect governance, compensation expectations, and dilution over time.
AlphAI scores every news story that mentions CING with an AI model for sentiment and relevance, and aggregates insider trades from Cingulate Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cingulate Inc. (CING) shares rose more than 4% in overnight trading after the USPTO allowed a patent application for a “Trimodal, Precision-Timed Pulsatile Release Tablet” tied to its ADHD drug platform. CING said the allowed status follows a filing in Nov 2023 and comes ahead of an FDA decision on CTx-1301, with a May 31 PDUFA target date.
4 min readCingulate Inc. (CING) filed its Q2 2026 10-Q. It reported $0 product revenue and a net loss of $5.87M for the three months ended June 30, 2026, versus a $4.98M net loss in the prior-year quarter. The company said it received an FDA complete response letter for CTx-1301 requesting additional CMC data and outlined CMC and launch preparation plans.
1 min readCingulate Inc. (CING) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness Cash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advan
6 min readCingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001862150 0001862150 2026-07-17 2026-07-17 0001862150 CING:CommonStockParValue0.0001PerShareMember 2026-07-17 2026-07-17 0001862150 CING:WarrantsExercisableForCommonStockMember 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES
2 min readCingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001862150 0001862150 2026-07-09 2026-07-09 0001862150 CING:CommonStockParValue0.0001PerShareMember 2026-07-09 2026-07-09 0001862150 CING:WarrantsExercisableForCommonStockMember 2026-07-09 2026-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES
4 min readCingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001862150 0001862150 2026-06-30 2026-06-30 0001862150 CING:CommonStockParValue0.0001PerShareMember 2026-06-30 2026-06-30 0001862150 CING:WarrantsExercisableForCommonStockMember 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES
4 min readHargroves Thomas Jeffrey purchased 97,276 indirectly-held shares of Cingulate Inc. (CING) at $5.04 ($0.49M total) on 2026-02-13.
2 min readHealthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin
6 min readHealthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show
5 min readCingulate Inc. (NASDAQ: CING) has filed an S-3 shelf registration statement to register 4.21 million shares of common stock for resale by selling stockholders. These shares include those issued in a January 2026 private placement, shares from preferred stock conversion, and shares issuable upon warrant exercise. The company will not receive proceeds from resales, but could receive approximately $9.4 million if warrants are fully exercised for cash, which would be used for regulatory approval, development, manufacturing, and commercialization of CTx-1301.
2 min read
